NEWS
2026.10.11NEWS
Vetanic to Present Cross-Species iPSC-Derived MSC Platform at ISSCR Kyoto 2026
Daisuke Kamiya, R&D Leader at Vetanic, will present a poster at the ISSCR iPSC 20th Anniversary Symposium, “20 Years of iPSC Discovery: A Celebration and Vision for the Future,” held in Kyoto, Japan, from October 20 to 22, 2026.
The presentation will report the establishment of iPSC lines from dogs, cats, and horses, and the characterization of mesenchymal stem cells derived from them (iMSCs). Human and canine iMSCs shared hallmark MSC properties, including surface antigen profiles and trilineage differentiation, as well as responsiveness to inflammatory cytokines and immunomodulatory capacity. iMSCs also showed higher proliferative capacity and younger gene expression signatures than adult tissue-derived MSCs. By eliminating donor-derived variability through a common manufacturing process, iMSCs may serve as a foundation for bidirectional translational research between humans and animals under the One Health concept. We look forward to seeing you at the poster session.
ISSCR iPSC 20th Anniversary Symposium (20 Years of iPSC Discovery: A Celebration and Vision for the Future)
Date: October 20 (Tue) – 22 (Thur), 2026
Venue: Kyoto International Conference Center, Kyoto, Japan
Poster Title: Bridging Species via iPSC-Derived MSCs: A Universal Platform for Cross-Species Comparative Medicine and One Health Innovations [Poster Session 1 / Poster Number 161]
Presenter: Daisuke Kamiya (R&D Leader)
Presentation time: October 20 (Tue), 17:00-17:45
https://www.isscr.org/upcoming-programs/2026-kyoto-international-symposium
2026.04.22NEWS
Presentation on Peripheral Nerve Cells Derived from Canine iPS Cells
Vetanic will present the results of our study on the differentiation of peripheral nerve cells from canine iPS cells and the functional analysis of these cells at the 24th Congress of the Japanese Society for Regenerative Medicine.
While we are currently developing canine iMSC products for veterinary regenerative medicine, we are also actively researching the differentiation of various cell types to demonstrate the potential of our technology. In a world-first achievement, we have successfully induced the differentiation of peripheral nerve cells from canine iPS cells. We will report these findings at the upcoming conference.
The 24th Congress of the Japanese Society for Regenerative Medicine
Date: March 20 (Thu) – March 22 (Sat), 2025
Venue: PACIFICO Yokohama, Kanagawa, Japan
Presentation Title: Induction of Differentiation and Functional Analysis of Peripheral Nerve Cells Derived from Canine iPS Cells [Oral Presentation O-15]
Presenter: Daisuke Kamiya (R&D Leader)
2026.04.01資金調達
Vetanic Enters into Capital and Business Alliance with Sysmex Corporation and Kohjin Bio Co., Ltd.
We are pleased to announce that we have entered into a capital and business alliance agreement with Sysmex Corporation [TSE Prime: 6869; Headquarters: Kobe, Hyogo] and Kohjin Bio Co., Ltd. [TSE Growth: 177A; Headquarters: Sakado, Saitama].
In the research and development of cell therapy and regenerative medicine products utilizing animal iPS cell technology in the field of veterinary medicine, we will promote collaboration to leverage Sysmex’s advanced analytical and quality control technologies, as well as Kohjin Bio’s strengths in custom culture media development. As a foundation for strengthening this partnership, we have executed a third-party allotment of new shares with both companies as allottees and established a capital alliance.
For further details, please refer to the attached PDF.
2025.02.22NEWS
Presentation on Peripheral Nerve Cells Derived from Canine iPS Cells
Vetanic will present the results of our study on the differentiation of peripheral nerve cells from canine iPS cells and the functional analysis of these cells at the 24th Congress of the Japanese Society for Regenerative Medicine.
While we are currently developing canine iMSC products for veterinary regenerative medicine, we are also actively researching the differentiation of various cell types to demonstrate the potential of our technology. In a world-first achievement, we have successfully induced the differentiation of peripheral nerve cells from canine iPS cells. We will report these findings at the upcoming conference.
The 24th Congress of the Japanese Society for Regenerative Medicine
Date: March 20 (Thu) – March 22 (Sat), 2025
Venue: PACIFICO Yokohama, Kanagawa, Japan
Presentation Title: Induction of Differentiation and Functional Analysis of Peripheral Nerve Cells Derived from Canine iPS Cells [Oral Presentation O-15]
Presenter: Daisuke Kamiya (R&D Leader)
2024.11.30NEWS
The patent for the establishment of animal iPS cells has been granted in Japan.
We are pleased to announce that we have been granted a patent in Japan for the foundational technology behind the establishment of animal iPS cells (Patent No. 7591219). This patent, based on the results of joint research by Keio University and Nihon University, was filed jointly, and Vetanic holds an exclusive license to its utilisation.
Establishing iPS cells (induced pluripotent stem cells) in various animal species other than mice has long been recognised as a challenge. These species, known as “Resistance to pluripotency induction”, contain many animals that are closely connected to humans, such as dogs and cats. Our technology founders – Professor and Director Hideyuki Okano of the Keio University Regenerative Medicine Center, Professor Seiji Shiozawa of the Disease Model Research Center at Kurume University School of Medicine, and Professor and Director Kazuya Edamura of the Nihon University Animal Medical Center at Nihon University College of Bioresource Sciences – have developed a proprietary method to stably induce iPS cells in these animal species and establish cell lines suitable for clinical applications.
This patent grant confirms the patentability of this method within Japan. Moving forward, we aim to secure patent approval for this technology in other countries as well.
Technical Details:
Establishing methods to produce iPS cells from various animal species – a critical resource forming the foundation of cell engineering using stem cells.2024.11.11NEWS
Announcement of Basic Agreement on Business Partnership with Kojin Bio Co., Ltd. for Product Development
We are pleased to announce that we have entered into a basic agreement on a business partnership with Kojin Bio Co., Ltd. (TSE Growth 177A, President: Takahito Nakamura) for “the development of animal iPS cell-derived regenerative medicine and related research-use products.”
Kojin Bio is a leading company in the regenerative medicine field, expanding its business domestically and internationally through the unique development of cell culture media and contract services for cell processing. Additionally, the company has engaged in pioneering research efforts in the field of veterinary medicine.
Through this partnership, we accelerate research and development, promote the manufacturing of higher-quality product, and expedite the early acquisition of marketing approval of our cell therapy product to achieve our goal of “global-standard animal regenerative medicine.” Furthermore, we collaborate with Kojin Bio to develop various animal iPS cell-derived cells for the purpose of basic research with their accumulated expertise.
Please refer to the PDF for further details. (JAPANESE language only)
2024.04.05ARTICLE
The article introducing Vetanic has been made available at Nikkei Biotechnology & Business Online on the 5th April 2024.
Please refer the online article from below URL link. (available to the subscription members only)
Nikkei Biotechnology & Business, 5th April 2024 特集連動◎多様化と高度化が進む動物薬 「Vetanic、イヌ・ネコのiPS細胞作製技術で複数疾患に対する再生医療等製品を開発」